Edwards Lifesciences Corporation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
Edwards Lifesciences Corporation (EW) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $300.00 thousand for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-25
- Edwards Lifesciences Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2025-09-30 was $300.00K.
- Edwards Lifesciences Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2025-06-30 was $300.00K.
- Edwards Lifesciences Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2025-03-31 was -$1.30M.
- Edwards Lifesciences Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for the quarter ending 2024-12-31 was $16.30M, a 11.89% decline year-over-year.
- Edwards Lifesciences Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $6.20M, a 8.77% increase from fiscal 2023.
- Edwards Lifesciences Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $5.70M, a 16.33% increase from fiscal 2022.
- Edwards Lifesciences Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $4.90M, a 7.55% decline from fiscal 2021.
- Edwards Lifesciences Corporation effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $5.30M, a 26.19% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 3 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 3 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 6 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 6 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 9 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 9 month as first filed | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | $300.00K 10-Q · filed 2025-11-05 | $600.00K derived: sum of 2 quarters · filed 2025-11-05 | -$800.00K 10-Q · filed 2025-11-05 | $15.60M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2025-06-30 | $300.00K 10-Q · filed 2025-08-06 | -$1.00M 10-Q · filed 2025-08-06 | $15.30M derived: sum of 3 quarters · filed 2026-02-25 | $14.70M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2025-03-31 | -$1.30M 10-Q · filed 2025-05-06 | $15.00M derived: sum of 2 quarters · filed 2026-02-25 | $14.40M derived: sum of 3 quarters · filed 2026-02-25 | $10.60M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-12-31 | $16.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $15.70M derived: sum of 2 quarters · filed 2026-02-25 | $11.90M derived: sum of 3 quarters · filed 2026-02-25 | $6.20M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | -$600.00K 10-Q · filed 2025-11-05 | -$4.40M derived: sum of 2 quarters · filed 2025-11-05 | -$10.10M 10-Q · filed 2025-11-05 | $8.30M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | -$3.80M 10-Q · filed 2025-08-06 | -$9.50M 10-Q · filed 2025-08-06 | $8.90M derived: sum of 3 quarters · filed 2026-02-25 | $7.10M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | -$5.80M 10-Q · filed 2025-05-06 | -$6.30M 10-Q · filed 2024-04-29 | $12.70M derived: sum of 2 quarters · filed 2026-02-25 | $10.90M derived: sum of 3 quarters · filed 2026-02-25 | $2.80M derived: sum of 4 quarters · filed 2026-02-25 | |||
| 2023-12-31 | $18.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $16.70M derived: sum of 2 quarters · filed 2026-02-25 | $8.60M derived: sum of 3 quarters · filed 2026-02-25 | $5.70M 10-K · filed 2026-02-25 | $6.60M 10-K · filed 2024-02-12 | |||
| 2023-09-30 | -$1.80M 10-Q · filed 2024-11-06 | -$1.90M 10-Q · filed 2023-10-27 | -$9.90M derived: sum of 2 quarters · filed 2024-11-06 | -$12.80M 10-Q · filed 2024-11-06 | -$14.20M 10-Q · filed 2023-10-27 | $28.80M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-06-30 | -$8.10M 10-Q · filed 2024-07-31 | -$9.30M 10-Q · filed 2023-07-28 | -$11.00M 10-Q · filed 2024-07-31 | -$12.30M 10-Q · filed 2023-07-28 | $30.60M derived: sum of 3 quarters · filed 2025-02-28 | $27.20M derived: sum of 4 quarters · filed 2025-02-28 | ||
| 2023-03-31 | -$2.90M 10-Q · filed 2024-04-29 | $38.70M derived: sum of 2 quarters · filed 2025-02-28 | $35.30M derived: sum of 3 quarters · filed 2025-02-28 | $15.50M derived: sum of 4 quarters · filed 2025-02-28 | ||||
| 2022-12-31 | $41.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $38.20M derived: sum of 2 quarters · filed 2025-02-28 | $18.40M derived: sum of 3 quarters · filed 2025-02-28 | $4.90M 10-K · filed 2025-02-28 | $5.80M 10-K · filed 2023-02-13 | |||
| 2022-09-30 | -$3.40M 10-Q · filed 2023-10-27 | -$23.20M derived: sum of 2 quarters · filed 2023-10-27 | -$36.70M 10-Q · filed 2023-10-27 | $19.40M derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2022-06-30 | -$19.80M 10-Q · filed 2023-07-28 | -$33.20M 10-Q · filed 2023-07-28 | $22.80M derived: sum of 3 quarters · filed 2024-02-12 | $9.90M derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2022-03-31 | -$13.40M 10-Q · filed 2023-04-28 | $42.60M derived: sum of 2 quarters · filed 2024-02-12 | $29.70M derived: sum of 3 quarters · filed 2024-02-12 | $3.40M derived: sum of 4 quarters · filed 2024-02-12 | ||||
| 2021-12-31 | $56.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-12 | $43.10M derived: sum of 2 quarters · filed 2024-02-12 | $16.80M derived: sum of 3 quarters · filed 2024-02-12 | $5.30M 10-K · filed 2024-02-12 | ||||
| 2021-09-30 | -$12.90M 10-Q · filed 2022-10-28 | -$39.20M derived: sum of 2 quarters · filed 2022-10-28 | -$50.70M 10-Q · filed 2022-10-28 | $500.00K derived: sum of 4 quarters · filed 2023-02-13 | ||||
| 2021-06-30 | -$26.30M 10-Q · filed 2022-07-29 | -$37.80M 10-Q · filed 2022-07-29 | $13.40M derived: sum of 3 quarters · filed 2023-02-13 | -$3.00M derived: sum of 4 quarters · filed 2023-02-13 | ||||
| 2021-03-31 | -$11.50M 10-Q · filed 2022-04-28 | $11.50M 10-Q · filed 2021-04-28 | $39.70M derived: sum of 2 quarters · filed 2023-02-13 | $23.30M derived: sum of 3 quarters · filed 2023-02-13 | $3.10M derived: sum of 4 quarters · filed 2023-02-13 | |||
| 2020-12-31 | $51.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-13 | $34.80M derived: sum of 2 quarters · filed 2023-02-13 | $14.60M derived: sum of 3 quarters · filed 2023-02-13 | $4.20M 10-K · filed 2023-02-13 | ||||
| 2020-09-30 | -$16.40M 10-Q · filed 2021-10-29 | -$36.60M derived: sum of 2 quarters · filed 2021-10-29 | -$47.00M 10-Q · filed 2021-10-29 | $33.10M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2020-06-30 | -$20.20M 10-Q · filed 2021-07-30 | -$30.60M 10-Q · filed 2021-07-30 | $49.50M derived: sum of 3 quarters · filed 2022-02-14 | $29.90M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2020-03-31 | $10.30M 10-Q · filed 2021-04-28 | $69.70M derived: sum of 2 quarters · filed 2022-02-14 | $50.10M derived: sum of 3 quarters · filed 2022-02-14 | $32.50M derived: sum of 4 quarters · filed 2022-02-14 | ||||
| 2019-12-31 | $59.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-14 | $39.80M derived: sum of 2 quarters · filed 2022-02-14 | $22.20M derived: sum of 3 quarters · filed 2022-02-14 | $3.20M 10-K · filed 2022-02-14 | ||||
| 2019-09-30 | -$19.60M 10-Q · filed 2020-10-26 | -$37.20M derived: sum of 2 quarters · filed 2020-10-26 | -$56.20M 10-Q · filed 2020-10-26 | $28.90M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-06-30 | -$17.60M 10-Q · filed 2020-07-27 | -$36.60M 10-Q · filed 2020-07-27 | $48.50M derived: sum of 3 quarters · filed 2021-02-12 | $35.60M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2019-03-31 | $19.00M 10-Q · filed 2020-04-28 | $66.10M derived: sum of 2 quarters · filed 2021-02-12 | $53.20M derived: sum of 3 quarters · filed 2021-02-12 | $35.90M derived: sum of 4 quarters · filed 2021-02-12 | ||||
| 2018-12-31 | $47.10M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-12 | $34.20M derived: sum of 2 quarters · filed 2021-02-12 | $16.90M derived: sum of 3 quarters · filed 2021-02-12 | $2.80M 10-K · filed 2021-02-12 | ||||
| 2018-09-30 | -$12.90M 10-Q · filed 2019-10-25 | -$30.20M derived: sum of 2 quarters · filed 2019-10-25 | -$44.30M 10-Q · filed 2019-10-25 | |||||
| 2018-06-30 | -$17.30M 10-Q · filed 2019-07-26 | -$31.40M 10-Q · filed 2019-07-26 | ||||||
| 2018-03-31 | $14.20M 10-Q · filed 2019-04-26 | |||||||
| 2017-12-31 | $3.90M 10-K · filed 2020-02-14 | |||||||
| 2016-12-31 | $3.60M 10-K · filed 2019-02-15 | |||||||
| 2015-12-31 | $2.30M 10-K · filed 2018-02-16 | |||||||
| 2014-12-31 | $2.10M 10-K · filed 2017-02-17 | |||||||
| 2013-12-31 | $2.60M 10-K · filed 2016-02-19 | |||||||
| 2012-12-31 | $1.90M 10-K · filed 2015-02-20 | |||||||
| 2011-12-31 | $1.90M 10-K · filed 2014-02-28 | |||||||
| 2010-12-31 | $1.90M 10-K · filed 2013-02-28 | |||||||
| 2009-12-31 | $1.40M 10-K · filed 2012-02-27 | |||||||
| 2008-12-31 | $900.00K 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |